| This week's sponsor is Premier Research. | | | How Psoriasis Treatment Advanced, and What's Next
Thanks to new biologics, more than half of treated psoriasis patients achieve essentially clear skin. Our white paper examines how we got here, and what's next. Premier Research. It's what we do. Best. |
Today's Rundown Startup Jnana raises $50M to tackle elusive membrane protein targets David Apelian jumps ship from Achillion As the door to possible Gilead buyout opens, Galapagos takes up filgotinib co-promotion option [Sponsored] How Real-World Evidence and Value-Based Contracts Can Help Payers and Manufacturers Find Common Ground in Rare Disease Celgene, CRT strike mRNA translation cancer R&D pact Alnylam back on track with fitusiran as FDA lifts clinical hold EuroBiotech Report—Gilead-Hookipa, Erytech fail, NASH startup, Vernalis-Daiichi and AMRC FiercePharmaAsia—Ono’s new BMS deal, Eisai’s Lenvima, Sanofi’s Dengvaxia testimony Chutes & Ladders—Teva’s former chairman resigns as ax falls on 14K jobs Featured Story | | | Friday, December 15, 2017 Little biotech startup Jnana Therapeutics has a big plan. It wants to unlock the potential of a massively underexplored class of membrane proteins it calls the cell’s "metabolic gates"—with the help of $50 million in first-round funding. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Friday, December 15, 2017 David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion. Friday, December 15, 2017 Galapagos has taken up its option to co-promote filgotinib with Gilead in certain European nations. The action is a big milestone on Galapagos’ path to becoming a commercial-stage biotech, but the news risked being overshadowed by news Gilead will be free to acquire its partner in two weeks. Monday, December 11, 2017 When payers and manufacturers brawl over pricing, patients with rare diseases can suffer. Is there any common ground? Both sides believe real-world evidence can help quantify the benefits of a medication, and value-based contracts can ensure patients reap the rewards. Thursday, December 14, 2017 Celgene has teamed up with Cancer Research Technology (CRT) to secure a source of oncology assets. The five-year pact puts CRT in charge of discovering drugs that affect protein assembly and taking them through phase 1. Friday, December 15, 2017 Alnylam, which put its hemophilia program on hold in September, has gotten the all-clear from the FDA to resume trials of its RNAi drug fitusiran. Thursday, December 14, 2017 In this week's EuroBiotech Report, Gilead backs Hookipa’s $60 million round, Erytech is hit by a cancer failure, Ex-Dezima executives plot a NASH trial and more. Friday, December 15, 2017 Bristol-Myers Squibb forms new immuno-oncology deal with Ono, Eisai's Lenvima wins NICE backing in kidney cancer, Sanofi tries to persuade Philippines lawmakers that Dengvaxia is safe and works to develop a solution for the fallout, and more. Friday, December 15, 2017 Teva’s former chairman and interim CEO Yitzhak Peterburg resigns amid sweeping job cuts, OrbiMed founder Sam Isaly steps down after harassment allegations, Grail poaches a Roche/Genentech executive to take the helm left by Huber, plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA BIO CEO & Investor Conference February 12-13, 2018 | New York, New York | 